SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that it has filed a preliminary prospectus supplement to a shelf registration statement with the Securities and Exchange Commission relating to a proposed public offering of 3,500,000 shares of its common stock. The underwriter will be granted the right to purchase up to an additional 525,000 shares of common stock. All of the shares are being sold by Illumina.
Goldman, Sachs & Co. is acting as sole manager of the offering.
This communication is not an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from the Prospectus Department of Goldman, Sachs & Co., 00 Burma Road, Jersey City, NJ 07305. Phone: 212-902-1171, Facsimile: 212-902-9316, and e-mail at prospectus-ny@ny.email.gs.com.
About Illumina
Illumina develops and markets next-generation tools for the large-scale analysis of genetic variation and function.
Contacts
Investors: Christian Henry Sr. Vice President & CFO 858-202-4508 chenry@illumina.com or Peter J. Fromen Sr. Director, Investor Relations 858-202-4507 pfromen@illumina.com or Media: Maurissa Bornstein Public Relations Manager 858-332-4055 mbornstein@illumina.com http://www.illumina.com/
